Very difficult to see AXGN not making a big run north. awe*some*sto-ck*s alerted a new stock just now. going to check it out.
In the short-term AXGN does not seem to be like a good trade. check out awe.som*sto-cks, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
Great news from last quarterly call about product use in mandible reconstructive surgery increasing the addressable market size by estimated $200MM annually. I think its especially powerful that the company did not pursue mandible reconstruction - a bunch of surgeons were looking around and thinking "what else can we do with this stuff?" And they solve a previously unmet medical need, and happen to create $200MM in potential additional market. For the longest time Axogen estimated the market at $1.6B, then with their most recent new product they increased it to $1.8B, and now with additional maxiofacial applications its $2B. When you play around with market cap numbers and wonder "how big could this get? How long can 40%+ revenue growth continue?" Its nice to think new applications and products continue to create ever more potential.
The scenarios are quite interesting at current levels for AXGN. if you guys have questions you should ask awesom*sto-cks. They often respond to my emails which is helpful.
Extreme volatility of this stock makes me suspect some sort of manipulation. After all it is suddenly up almost 5% on no new news. In fact after good earnings it went down for a few days and is still way below its high in the low 17s. I am beginning to suspect that buyout talk is just that talk.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks 1,000 Day Parameter 2,926 NASDAQ Stocks Price Correlation Histogram Type Description 1. Zero Correlation Histogram - The stock pair is concentrated in the correlation coefficie
The Top Newsletter for NASDAQ & NYSE cheapies that make HUGE GAINS --> go to Penny St0cklOl.0rg
Up on a very down day. I think is a takeover candidate. JNJ or Boston Scientific ?
+86pct on their last NASDAQ Alert --> T0pMarketGalners.c0m
Great 2nd Qt. Beat on revenues and share price.
AxoGen beats by $0.02, beats on revenue
Aug. 2, 2017 4:02 PM ET|By: Mamta Mayani, SA News Editor AxoGen (NASDAQ:AXGN): Q2 EPS of -$0.06 beats by $0.02.
Revenue of $15.17M (+46.1% Y/Y) beats by $0.79M. up 4% AH
there is a new price target $22 bucks
The trading setup for AXGN looks very enticing. awesom*stocks just allerted a new stock - it beats having to dig online yourself for new stock ideas.
jerry got it from stock news .com Leerick Partners july 31, 2017 6:45 am PT $22 says new coverage bullish!!! by STOCK NEWS . COM STAFF